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CObjective: Our objective is to review and assess the main pharmaceu-
tical cost-containment policies used in Ireland in recent years, and to
highlight how a policy that improved fiscal sustainability butworsened
economic sustainability could have improved both if an option-based
approach was implemented. Method: The main public pharmaceuti-
cal cost-containment policy measures including reducing the ex-fac-
tory price of drugs, pharmacy dispensing fees and community drug
scheme coverage, and increasing patient copayments are outlined
alongwith the resulting savings.We quantify the cost implications of a
new policy that restricts the entitlement to free prescription drugs of
persons older than 70 years and propose an alternative option-based
policy that reduces the total cost to both the state and the patient.
Results: This set of policy measures reduced public spending on com- O
o rep
utive
al So
oi:10.1016/j.jval.2011.10.007unity drugs by an estimated €380m in 2011. The policy restricting free
rescription drugs for persons older than 70 years, though effective in
educing public cost, increased the total cost of the drugs supplied. The
olicy-induced cost increase stems from a fees anomaly between the
wo main community drugs schemes which is circumvented by our
lternative option-based policy. Conclusions: Our findings highlight
he need for policymakers, even when absorbed with reducing cost, to
esign cost-containment policies that are both fiscally and economi-
ally sustainable.
eywords: community drug schemes, cost-containment policies, phar-
aceutical costs, efficiency, option., sustainability.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Pharmaceutical expenditure in the European Union (EU) exceeded
€180 billion in 2008 and accounted, on average, for around 17% of EU
countries’ total expenditure on health [1]. The scale and growth of
these costs challenge the ongoing sustainability of some national
health systemsand thekeyvaluesofuniversal coverage, solidarity in
financing, equity of access, and the provision of high-quality health
care (Council of the European Union 2006) that underlie them.
Health system sustainability has been defined by the World
Health Organization as the “ability to meet the needs of the pres-
ent without compromising the ability to meet future needs” [2]. A
health system is fiscally sustainable if government is able and
willing to meet its health system obligations. It is economically
sustainable “so long as the value produced by health care exceeds
its opportunity cost” [3]. In Ireland, particular concerns over sus-
ainability have arisen with regard to public expenditure on com-
unity medicines, which had increased more than sixfold from
300 million in 1998 to €1.9 billion in 2008 [4]. Irish research has
used the shares of pharmaceutical expenditure in total public ex-
penditure and the growth in health expenditure, both public and
private, as a proportion of national income asmetrics of fiscal and
economic sustainability, respectively [5].
Fractured national public finances, headline deficits, and the ele-
vated fiscal risks recently noted by the International Monetary Fund
(IMF) have impaired the funding capacity of governments and fo-
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ublished by Elsevier Inc.cused increasing policy attention on fiscal sustainability [6]. Fiscal
stress arising from escalating public health costs has resulted in in-
creasing international reliance onpharmaceutical cost-containment
policies. A consensus policy strategy that ensures fiscal and eco-
nomic sustainability, however, has not yet crystallized.
Tele and Groot [7] and Barros [8] assess the effectiveness of
policies adopted in the EU27. These include international refer-
encing to benchmark countries with lower prices, internal refer-
ence pricing systems to promote price competition in domestic
markets, and positive lists for reimbursement to promote con-
sumption of generics (including in some cases substitution by
pharmacists of drugs prescribed by physicians). They found no
“silver bullet” in the measures they investigated.
Tele and Groot found thatmost cost-containment policies con-
sist of supply-side measures, as they have proved to be more ef-
fective than demand-sidemeasures and that price control policies
are most effective in controlling expenditure when accompanied
by complementary volume control measures.
Barros found that fewmeasures are universally effective (apart
fromgeneric substitution combinedwith reference pricing). Some,
such as positive lists, prescribing budgets, and reference pricing,
were effective in some countries but only in the short term [9–13].
Ironically, some cost-containment policies may reduce rather
than increase the efficient use of limited health-care resources.
For example, volume or profit controls, rebates or paybacks, can
achieve short-term savings but by inhibiting access to treatments
ort.
, Aras Slainte, Floor 3, Wilton Road, Cork, Ireland.
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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390 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 3 8 9 – 3 9 3for patients who need them and discouraging health-care innova-
tion they may negatively impact health outcomes, medical inno-
vation, and long-term health costs [14].
Medicare Part D is a federal program to subsidize the costs of
prescription drugs for Medicare beneficiaries in the United States
and may be a useful international reference for pharmaceutical
cost-containment policies. It was intended to lower cost, increase
efficiency, and broaden access tomedicines butmay have resulted
in higher prescription drug prices (25% increase for an elderly per-
son in the year after he or she became eligible) [15], large coverage
gaps, higher copayments for brand names, and significant copay-
ment premiums for various patient cohorts [16]. Nobel Prize win-
ner Daniel McFadden concludes, however, that it is too early to
establish the long-term consequences of this program [11].
Escalating public health costs and stressed public finances also
crystallized the need for fiscal sustainability and have compelled
rapid policy change in Ireland. Public health expenditure in Ire-
land more than doubled between 2000 and 2008, rising to €15.186
billion [17] (75% of all health expenditure) [1]. During this period,
reland had the third fastest growth rate (7.6% per annum) in per-
apita real health expenditure of all Organisation for Economic
o-operation and Development (OECD) countries [18]. In 2008, it
pent $3784 per capita on health, more than the OECD average of
3060 (both adjusted for purchasing power parity), even though
ignificantly less than the US expenditure of $7720 per capita [1].
reland spent $654 per capita on pharmaceuticals in 2008, third
ighest in the OECD behind the United States and Canada [1].
The Irish economy has contracted sharply since 2008. Deep
ecession, historic fiscal deficits, and mounting public debt culmi-
ated in an €85 billion EU–IMF funding package granted in Novem-
er 2010 on condition that the Irish government raises taxes and
educes public spending equivalent to 9% of GDP over 2011-2014
19]. Faced with such circumstances a government that is unable
r unwilling tomeet its health system obligationsmust 1) increase
ublic health revenues, 2) weaken public health obligations, or
) improve health system conversion of resources into value [3].
Although recent Irish policymaking has applied all three
emedies, its focus has been on the third, containing costs and
imiting disruption to the supply of public medical services by
eeking greater efficiency [20], a theme echoed in The National
ecovery Plan 2011-2014: “the focus must be on eliminating inef-
ciencies . . . and [to] lessen the impact on service provision” [21].
he public health allocation, accounting for 27% of the total public
urrent expenditure, has been cut [20]. The Health Service Execu-
ive (HSE), which is responsible for delivering health and social
are in Ireland, saw its gross budget fall by 9% from the beginning
f 2009 to €13.4 billion bymid-year 2011 [22]. Expenditure on phar-
acy drugs/medicines and fees under the General Medical Ser-
ices (GMS) scheme fell by 18% during the same 30-month period,
ringing it back to €1075 million [22].
Our article has three key objectives. The first is to sketch the
ain policy measures recently adopted to contain public sector
harmaceutical costs in Ireland and to provide estimates of full-
ear savings for 2011. The second is to examine a policy that in-
reased public health revenue and reduced public health obliga-
ions but, because of a pricing anomaly in the “design” of the
ommunity drug schemes, did so at the expense of converting
esources into value. The third is to show that when the preferred
emedy of removing the anomaly is not available, it is still possible
o construct a “second-best” option-based remedy to regain both
scal and economic sustainability.
Methods
First, we categorize and quantify the main policy measures re-
cently adopted to contain public pharmaceutical costs in Ireland
under three headings: 1) the ex-factory price of drugs, 2) pharmacy sdispensing fees andmarkups, and 3) scheme coverage and patient
copayments.
Second, until January 2009, the GMS scheme, the largest com-
munity drug scheme that covers 1.68 million [22] people or 37% of
the Irish population, automatically covered all persons older than
70 years as well as all persons who are unable to pay for medical
services, including prescribed drugs, “without undue hardship.”
This meant that the older persons’ drug costs were borne fully by
the HSE. We identified and extracted these drug costs of persons
older than 70 years from the Primary Care Reimbursement Service
database prepolicy change.
In January 2009, the Irish government introduced an income-
based means test to determine GMS entitlement to free prescrip-
tion drugs for persons older than 70 years. After this policy change,
elderly persons who failed the means test lost GMS cover but be-
came automatically entitled to the less advantageous Drug Pay-
ments Services (DPS) scheme. Under this scheme, they pay the
first €120 of their monthly expenditure (€1440 per annum) on pre-
scribed drugs and the HSE pays any remaining or excess costs.
The Irish government contracts private pharmacies to dis-
pense doctor-prescribed drugs and medicines to persons covered
by its community drug schemes. Pharmacists, however, charge a
20% markup on the medical ingredient cost of drugs dispensed
under the DPS scheme. This increases DPS drug prices by 16%
because medical ingredients, which exclude payments made for
wholesale delivery, pharmacy dispensing fees, and retail markup,
typically make up around 80% of total drug costs. No suchmarkup
applies to the GMS scheme.
We then calculated the postpolicy cost of these drugs, includ-
ing the additional markup. We compared the public, private, and
total drug costs of persons older than 70 years pre- and postpolicy
change. Clearly, a fall in public cost improves fiscal sustainability,
but a rise in total cost corrodes economic sustainability.
Third, it is still possible to construct an option-based policy to
enhance both fiscal and economic sustainability even if the re-
moval of the DPS markup is resisted. This can be done by offering
persons older than 70 years, who are no longer entitled to free GMS
scheme drugs, the option to retain this service for a fixed annual
option premium or price. Those who do not activate the option
remain automatically eligible for the DPS, as before, and are not
impacted by the policy.
The patient benefits, provided the annual option premium P is
ess than the 12 monthly DPS copayments, 12K, they would other-
ise pay. Persons spending more than €120 per month benefit if
 12K and save 12K  P annually.
The HSE benefits from the 12K it receives in DPS patient co-
ayments, but because of the DPS markup m, it has to pay an
xtra mD for the same drugs that formerly cost that patient D
hen they had GMS cover. The HSE, therefore, receives a net
ontribution of 12K  mD from this DPS patient. If the patient
opts instead to hold GMS cover and pays the HSE an option
premium P that exceeds 12K  mD, then the HSE benefits and
saves P  12K  mD.
The HSE would offer the option and the patient would take it up
nly if it benefitsbothparties.This requires theoptionpremiumtobe
et in the range 12KmD P 12K. higherpremiumbenefits theHSE
ore: a lowerpremiumbenefits thepatientmore; thechosenpremium
settles the distribution of the cost savingmD between them.
Efficiency requires the drugs to be supplied at the lowest pos-
ible cost D. Accordingly, mD is the cost saving from distributing
he same drugs under the GMS scheme instead of the DPS scheme.
mplementation costs reduce this gross saving vis-à-vis the pre-
erred alternative of purging the pricing anomaly entirely, but the
ption has the attraction of being practicable when the pricing
tatus quo is uncorrectable.
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The annual cost to the Irish government of supplying medicines
exceeded €2.24 billion in 2008, a greater than sixfold increase in
ore than a decade [23]. This level of growth in expenditure is
nsustainable and has resulted in the implementation of various
harmaceutical cost-containment policy measures in Ireland,
hich include the following.
The ex-factory price of drugs
A 2006 agreement between the HSE and the Irish Pharmaceutical
Healthcare Association on the supply of medicines is estimated to
have delivered total savings of €250 million by September 2010
[20]. This agreement has been extended to 2012. It references and
links the price of new medicines in Ireland to nine EU member
states and reduced the price of patent-expiredmedicines[24]. Also
agreed are price cuts of 40% on 300 of themost common off-patent
drugs and 20% or 30% on generic drugs. These measures are in-
tended to ensure that the HSE no longer pays a premium price for
patent-expired medicines [25].
Pharmacy dispensing fees and mark-ups
The Report of the Independent Body on Pharmacy Contract Pricing
resulted in a restructuring of the GMS pharmacy dispensing fee sys-
tem [26]. From 2009, the new GMS fee-per-item is stepped; the fee-
per-item pharmacies receive falls as the number of items dispensed
exceeds given thresholds. The HSE also reduced the DPS pharmacy
retail markup on medical ingredients from 50% to 20% and reduced
wholesale factory-to-pharmacy markup from 17.66% to 8% [27].
Scheme coverage and patient copayments
Theminister restricted GMS coverage for high-income persons older
than 70 years in January 2009 and increased the DPS patient copay-
ments from €100 to €120 a month in the 2010 budget. A €0.50 charge
per GMS item was also introduced in October 2010; however, the
Health Minister has subsequently promised to remove this.
Thesemeasureseffectively enhancedfiscal sustainability andare
estimated to reduce the annual public cost of pharmaceuticals under
the community drug schemes by €380 million in 2011. Table 1 sum-
marizes these details [28].
Other measures proposed, but not yet fully adopted, include a
model for reference pricing and generic substitution, increased ex-
pert feedback to general practitioners on quality prescribing indica-
tors, reviewing the reimbursement status of clinical nutritional and
similarproducts, and the increaseduseof cost-effectivenessanalysis
[29,30]. More recently, reducing the fees payable to general practitio-
ners for immunization services is also being considered[31].
Table 1 – Recent pharmaceutical cost containment policies
Policy M
Ex-factory price of drugs ● 40% price cut on 300 most commo
● 20% and 30% price cut on generic
Pharmacy dispensing fees
and markups
● Reduction in payments to commu
structure, reducing patient care fe
● DPS scheme retail markup reduce
● Wholesale markup reduced from
Scheme coverage and patient
copayments
● Restricted GMS scheme coverage
● Increase monthly DPS copaymen
● Enhance probity in payments and
TotalDPS, Drug Payments Services; GMS, General Medical Services.Sustainability of policy for persons older than 70 years
The policy removing free community drug entitlements from a
small portion of the over-70s population enhanced fiscal sustain-
ability but worsened Irish economic sustainability, as it reduced
the public cost but increased the total cost of providing the same
drugs.
Public spending on GMS prescription drugs in Ireland was ap-
proximately €1845 for persons older than 70 years in 2009. This is
calculated by using the average GMS cost ofmedicines for persons
aged 70–74 years (€1641) and persons older than 75 years (€1961) as
presented in the Primary Care Reimbursement Service 2009 An-
nual Report [32] and multiplying by the proportion of the over-70
Irish population in both age groups (0.36 and 0.64, respectively).
Before the policy change, this cost fell entirely on the HSE as a
public cost. After the policy change, the same drugs now attract an
additional DPS markup that increases the overall total cost to
€2140. Withdrawing GMS cover increases total per-person drug
costs by €295, or 16%, which is received by community pharma-
cists. The older person’s private drug costs increase from nil to a
maximum of €1440 (i.e., 12 monthly copayments of €120): the HSE
ays the remaining drugs costs, a minimum of €700. This means
hat the annual public HSE costs per person fall from €1845 under
he GMS scheme to a minimum of €700 under the DPS scheme,
roducing amaximumpublic saving of €1145. An estimated 5%, or
7,671 persons older than 70 years, lost GMS cover [33]. This im-
lies an HSE saving of approximately €20.2 million (i.e., 17,671 
1145) in public costs, whereas the private cost increased from nil
o approximately €25.4million (i.e., 17,671 €1440). In total, it now
osts €5.2 million (i.e., 17,671  €295) more to provide the same
ommunity drugs. Hence, although the policy successfully re-
uced public cost and enhanced fiscal sustainability, it also re-
uced economic efficiency and increased the total cost of provid-
ng the same level of service.
Our proposed alternative option-based policy voids the addi-
ional cost by helping to restore the ex ante GMS coverage. Con-
ider an older person who, instead of losing GMS entitlement and
ncurring €1440 on monthly DPS copayments, opts instead to re-
ain GMS cover for a premium of, say, €1250. The option saves the
lder person €190 per annum. TheHSE offsets their €1845 drugs bill
ith the €1250 premium it receives, which leaves a net public cost
f just €595, which is €105 less than the cost of the current policy.
he HSE and the patient both gain from the more efficient option-
ased policy proposed. Table 2 summarizes these outcomes.
Discussion
The policy measures adopted in Ireland are estimated to reduce
the public cost of community drugs by €380 million in 2011, which
eland.
res Estimated 2011 savings
(in million euros)
-patent drugs
s
200
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% to 8%
100
rsons older than 70 years
€100 to €120
me verification
80
380in Ir
easu
n off
drug
nity
es an
d fro
17.66
for pe
t from
sche
ealth
392 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 3 8 9 – 3 9 3is all the more impressive given the rapid increase in numbers
covered by the GMS scheme.
The policymeasures reducing ex-factory drug prices and phar-
macy dispensing fees were effective in reducing the total resource
cost of delivering a given supply of drugs and enhanced both fiscal
and economic sustainability. Increased patient copayments do
not increase the total cost of a given basket of drugs, but they do
increase the patients’ cost. TheMcFadden andBarros findings sug-
gest that this may, over time, discourage patient access to medi-
cines, shrink their drugs basket, and negatively impact health out-
comes, long-term costs, and efficiency. Establishing the scale of
these health impacts is critical in constructing well-founded evi-
dence-based policies and requires detailedmodeling of both long-
term and short-term policy consequences in a fuller cost–benefit
analysis of outcomes, which is not undertaken here. Absent this,
what remains clear and indisputable, however, is that restricting
access of persons older than 70 years to GMS cover increases the
total cost of delivering a given supply of drugs. Our option-based
policy demonstrates this as it restores GMS cover and delivers the
same basket of drugs at a lower cost. If older people who lose GMS
cover consequently ration their use of appropriate medications,
increasing illness prevalence, hospital stays, and expensive
health-care treatments, it worsens economic sustainability and
reinforces the case for policy adaptation[34].
The cost inefficiency we highlighted stems from the inconsis-
tent GMS andDPS pharmacy fees that are the resistant outcome of
successive historic negotiations. Pharmacists strongly and, until
2010, successfully resisted the HSE-negotiated reduction in the
DPS markup from 50% to its present 20% level because it reduced
pharmacy revenues. The public savings from this and other drug
policies brought pharmacy incomes back to levels paid in 2006,
according to the Department of Health and Children [35], reducing
pharmacy incomes on average by €100,000 per annum [36]. Phar-
macies also lost asmany as 1600 jobs in the 9months to April 2010
[36] and are resolutely opposed to any further erosion of the 20%
DPS markup that has been maintained in the June 2011 Statutory
Instrument [37].
Even if the fees anomaly persists, we have shown how the HSE
and the patient alike can avoid the additional drug costs by adopt-
ing the option-based policy. The gain from doing so increases with
the cost of drugs and decreases with the DPS markup and any
administration charges arising. Higher DPS copayments transfer
more of the gain to the HSE; a lower option price transfers more of
it to the patient. Patients at higher medical risk have the strongest
incentive to takeup the option, capping their drug costs at the option
premium. Patients at lower medical risk have the weakest incentive
to take up the option, but their drug costs tend to fall below the DPS
copayment threshold and are borne privately, so the HSE public cost
is largely unaffected if they do not activate the option. Although the
€5.2 million option efficiency benefit to be shared between the HSE
and the patient is small—just more than 1% of the €380 million an-
nual public savings we documented in Table 1—its importance is
disproportionate to its size for a number of reasons.
First, the Special Group on Public Service Numbers and Expen-
diture Programmes (2009) recommended €5.3 billion in public ex-
penditure savings, including recommending that only those with
Table 2 – Cost savings if an “over 70” buys a € option and r
Costs/policies Over 70 transfers from
GMS to DPS scheme (€)
O
Total Drug Cost 2140
Patient/private cost 1440
HSE/public cost 700
DPS, Drug Payments Services; GMS, General Medical Services; HSE, Hincomes less than the basic rate of social welfare should receiveGMS cover [38]. A special Central Statistics Office Survey of Income
and Living Conditions tabulation indicates that this recommenda-
tion would reduce GMS cover by approximately 1 million persons.
GMS medicines cost €852 per person covered in 2009, so the state
would save €852 million gross. Nevertheless, the total cost of the
same drugs, if dispensed under the DPS scheme, would be €988 or
€136 million (i.e., 16%) more. Because 41.7% of DPS-covered per-
sons claimed and received an average payout of €392 in 2009, this
resulted in an average public cost of €164 (i.e., 0.417  €392) per
DPS-eligible person. If the state contributed €164 million toward
the €988 million drug bill of 1 million new DPS patients, it would
save €688 million (€852–€164 million) net in public drug costs and
the citizenswould pay the remaining €824million. The key point is
that the cost of the same drugs increases by €136 million, regard-
less of how the state shares the burden with its citizens.
Second, this proposal would increase the total cost of drugs by
16% because of the DPS markup. One million lower-income per-
sons affectedwould be forced to paymost of these drug costs (€852
plus 16% on average), without any public contribution, as most of
them would fall below the annualized DPS copayment threshold.
Third, the loss of GMS entitlement and uncertain future med-
ical cost of those older than 70 years provoked an unexpected and
unprecedented public protest that injured the standing of govern-
ment. Future governments, IMF imperatives notwithstanding,
may balk at the Special Group proposal because it would scale up
the number losing GMS cover more than 50-fold. Our proposed
option-based alternative is more palatable: it is less costly by at
least €136million, and it allows thosewith greatermedical need to
retain GMS eligibility and to cap their drug costs.
Conclusions
The Irish health system has recently implemented pharmaceuti-
cal cost-containment policies, reducing annual public health drug
expenditure by more than €380 million in 2011 and enhancing
fiscal sustainability. Although the policy of restricting GMS cover
among persons older than 70 years reduced public spending, it
also reduced the economic sustainability of the Irish health sys-
tem. Our alternative option-based policy voids the policy-induced
cost increase, helps restore efficiency, and shares the gain be-
tween the state and the patient. It also encourages those with
higher medical risk and those who are most-risk averse to cap
their drug costs whereas those with lower medical risk are unaf-
fected by the policy.
Our findings affirm the need for policymakers, even when ab-
sorbedwith reducing cost, to design policy instruments that avoid
the negative effects of prioritizing cost containment over health
financing policy goals and inadvertently weakening the health
system’s economic sustainability.
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